Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2282119rdf:typepubmed:Citationlld:pubmed
pubmed-article:2282119lifeskim:mentionsumls-concept:C0028131lld:lifeskim
pubmed-article:2282119lifeskim:mentionsumls-concept:C0030015lld:lifeskim
pubmed-article:2282119lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:2282119lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:2282119lifeskim:mentionsumls-concept:C0008003lld:lifeskim
pubmed-article:2282119lifeskim:mentionsumls-concept:C1611588lld:lifeskim
pubmed-article:2282119pubmed:issue7-8lld:pubmed
pubmed-article:2282119pubmed:dateCreated1991-3-18lld:pubmed
pubmed-article:2282119pubmed:abstractTextThe two enantiomers of the potent muscarinic ligand 2-methyl-5[(dimethylamino)methyl]-3-oxo-isoxazolidine methiodide [(+/-)-V] were synthesized in a very high enantiomeric excess (98.8 and greater than 99%). The muscarinic activity of the two enantiomers was assayed on the isolated guinea pig ileum and atria, and on rat jejunum and urinary bladder and the nicotinic activity was evaluated on the frog rectus abdominis muscle. (R)-(-)-V, the most potent enantiomer in the muscarinic tests, has the same absolute configuration as [2R,5R]-muscarone and, like muscarone, has a low eudismic ratio (ER: 2.5-10.4). In the nicotinic assay, (S)-(+)-V was found to be the eutomer (ER: 3.5).lld:pubmed
pubmed-article:2282119pubmed:languageenglld:pubmed
pubmed-article:2282119pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2282119pubmed:citationSubsetIMlld:pubmed
pubmed-article:2282119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2282119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2282119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2282119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2282119pubmed:statusMEDLINElld:pubmed
pubmed-article:2282119pubmed:monthJullld:pubmed
pubmed-article:2282119pubmed:issn0014-827Xlld:pubmed
pubmed-article:2282119pubmed:authorpubmed-author:GrantPPlld:pubmed
pubmed-article:2282119pubmed:authorpubmed-author:ZontaFFlld:pubmed
pubmed-article:2282119pubmed:authorpubmed-author:LucchelliAAlld:pubmed
pubmed-article:2282119pubmed:authorpubmed-author:De MicheliCClld:pubmed
pubmed-article:2282119pubmed:authorpubmed-author:De AmiciMMlld:pubmed
pubmed-article:2282119pubmed:issnTypePrintlld:pubmed
pubmed-article:2282119pubmed:volume45lld:pubmed
pubmed-article:2282119pubmed:ownerNLMlld:pubmed
pubmed-article:2282119pubmed:authorsCompleteYlld:pubmed
pubmed-article:2282119pubmed:pagination859-66lld:pubmed
pubmed-article:2282119pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:meshHeadingpubmed-meshheading:2282119-...lld:pubmed
pubmed-article:2282119pubmed:year1990lld:pubmed
pubmed-article:2282119pubmed:articleTitleNitrile oxides in medicinal chemistry. 3. Synthesis and bioenantioselectivity of (+)- and (-)-2-methyl-5-[(dimethylamino)-methyl]-3-oxo-isoxazolidine methiodide.lld:pubmed
pubmed-article:2282119pubmed:affiliationIstituto Chimico-Farmaceutico, Università di Milano, Italy.lld:pubmed
pubmed-article:2282119pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2282119pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:2282119pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed